Phase 1/2a First-In-Human Study Of BMS-986218 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Phase 1/2 First-In-Human Study Of BMS-986249 Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) Read more
A Phase I Study to Evaluate the pharmacokinetics and safety of Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple Myeloma who have normal and varying degrees of impaired hepatic function (DREAMM 13) Read more
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody Read more
A Phase Ib Study Of SAR650984 (Anti-CD38 Mab) In Combination With Carfilzomib For The Treatment Of Relapsed Or Refractory Multiple Myeloma Read more
A Phase 3 Randomized Study Comparing Teclistamab In Combination With Daratumumab SC (Tecdara) Versus Daratumumab SC, Pomalidomide And Dexamethasone (Dpd) Or Daratumumab SC, Bortezomib, And Dexamethasone (Dvd) In Participants With Relapsed Or Refractory Multiple Myeloma Read more
Treatment Patterns And Adverse Event Management In Patients Treated With Selinexor In Combination With Other Approved Agents For Relapsed/Refractory Multiple Myeloma: Real-World Evidence Based On Electronic Medical Record Data Read more
